R&D

TGV-inhalonix believes that innovative medicines are the future to overcome resistant lung infections. Our goal is to develop and commercialize Mul-1867 – an investigational product that is a new class of antimicrobial therapeutics to address unmet needs in the cystic fibrosis patient community.

LEARN MORE ABOUT TGV-INHALONIX PIPELINE